Torbay man is first in the region to receive new prostate cancer therapy


Torbay Hospital has become the first in the UK to offer a pioneering new radiotherapy treatment for prostate cancer, which delivers a higher, more targeted dose of radiotherapy directly to the tumour, reducing the risk of the cancer spreading or returning while limiting damage to healthy tissue nearby.
A man from Torbay has become the first patient in Torbay and South Devon to receive a pioneering new radiotherapy treatment for prostate cancer, after the therapy was approved for national rollout by NHS England in June.
Stephen Dwyer-Lapthorne was diagnosed with localised prostate cancer in October 2025 and has been receiving stereotactic ablative radiotherapy, known as SABR, at Torbay Hospital.
Stereotactic ablative radiotherapy (SABR) delivers targeted, higher dose radiotherapy directly to the tumour to help reduce the risk of cancer spreading or returning. It is typically delivered in five doses, known as fractions, during a two-week period, compared to 20 doses using standard (external beam) radiotherapy.
The treatment delivers a higher, more targeted dose of radiotherapy directly to the tumour, in an effort to reduce the risk of the cancer spreading or returning while limiting damage to healthy tissue nearby.
This will mean far fewer hospital visits for patients.
Mr Dwyer-Lapthorne said: “I was so pleased to be offered SABR at Torbay Hospital I only have one session (fraction) left of the planned five sessions, and right now, I don’t feel anything, other than slightly fatigued, although I’m expecting potential side effects later.”
He said he was due to meet the review radiographer once his treatment had finished for another PSA test, ahead of a six-week follow-up appointment.
Naomi Hopkins, head of radiotherapy at Torbay and South Devon NHS Foundation Trust, said: “This national rollout is fantastic news for patients, giving Stephen and thousands of other men with a low or intermediate risk of prostate cancer access to SABR." She said the trust was "delighted that we are delivering prostate SABR locally, helping patients receive their treatment closer to home without needing to travel far.”
Prostate cancer is the most common cancer among men in the UK, with more than 55,000 diagnosed and around 12,300 dying from the disease each year. NHS England estimates around 17,500 men are diagnosed with low or intermediate-risk prostate cancer in England annually, and that up to a fifth of them, around 3,500 men, may choose SABR as their treatment option.
The rollout, backed by government investment in new radiotherapy machines, is expected to be available at all 48 radiotherapy centres across England.